Gallbladder cancer
Gallbladder cancer (GBC) is the most common cancer of the biliary tract, characterized by a
very poor prognosis when diagnosed at advanced stages owing to its aggressive behaviour …
very poor prognosis when diagnosed at advanced stages owing to its aggressive behaviour …
New horizons for precision medicine in biliary tract cancers
JW Valle, A Lamarca, L Goyal, J Barriuso, AX Zhu - Cancer discovery, 2017 - AACR
Biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, are poor-
prognosis and low-incidence cancers, although the incidence of intrahepatic …
prognosis and low-incidence cancers, although the incidence of intrahepatic …
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Background Systemic therapies for metastatic biliary tract cancers are few, and patients
have a median overall survival of less than 1 year. MyPathway evaluates the activity of US …
have a median overall survival of less than 1 year. MyPathway evaluates the activity of US …
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
JJ Harding, J Fan, DY Oh, HJ Choi, JW Kim… - The Lancet …, 2023 - thelancet.com
Background HER2 is overexpressed or amplified in a subset of biliary tract cancer.
Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, exhibited …
Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, exhibited …
Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma
Background & Aims In recent years, intrahepatic cholangiocarcinoma (iCCA) has evolved as
a “role model” for precision oncology in gastrointestinal cancers. However, its rarity, paired …
a “role model” for precision oncology in gastrointestinal cancers. However, its rarity, paired …
[HTML][HTML] Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update
Gallbladder cancer is a malignancy of biliary tract which is infrequent in developed countries
but common in some specific geographical regions of developing countries. Late diagnosis …
but common in some specific geographical regions of developing countries. Late diagnosis …
Overview of current targeted therapy in gallbladder cancer
X Song, Y Hu, Y Li, R Shao, F Liu, Y Liu - Signal Transduction and …, 2020 - nature.com
Gallbladder cancer (GBC) is rare, but is the most malignant type of biliary tract tumor.
Unfortunately, only a small population of cancer patients is acceptable for the surgical …
Unfortunately, only a small population of cancer patients is acceptable for the surgical …
HER2 expression status in diverse cancers: review of results from 37,992 patients
M Yan, M Schwaederle, D Arguello, SZ Millis… - Cancer and Metastasis …, 2015 - Springer
Human epidermal growth factor receptor 2 (HER2) amplification/overexpression is an
effective therapeutic target in breast and gastric cancer. Although HER2 positivity has been …
effective therapeutic target in breast and gastric cancer. Although HER2 positivity has been …
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study …
Background HER2 overexpression or amplification, which is present in 15% of all cases of
biliary tract cancer, has been identified as a druggable molecular target by genomic …
biliary tract cancer, has been identified as a druggable molecular target by genomic …
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications
Background Cholangiocarcinoma (CCA) is clinically heterogeneous; intra and extrahepatic
CCA have diverse clinical presentations. Next generation sequencing (NGS) technology …
CCA have diverse clinical presentations. Next generation sequencing (NGS) technology …